STAAR Surgical (STAA) Faces A Fresh Asia Pacific Test As Fair Value Stays In Focus
STAAR Surgical (STAA) has appointed Pascal Aeschlimann as Vice President of Asia Pacific, effective 2 November 2026. He will oversee commercial activity across the region excluding China, where demand for vision correction is rising.
STAAR Surgical shares recently closed at US$24.56, with a 7 day share price return of 8.62% and a 30 day share price return of 8.62%. However, longer term total shareholder returns over 1, 3 and 5 years are all negative and suggest momentum has been weak despite management moves such as the new Asia Pacific leadership hire.
Scan how STAAR Surgical compares with other vision related opportunities by reviewing the hand picked 34 healthcare AI stocks that could be shaping the next wave of eye care solutions.
STAAR Surgical has climbed in the short term while longer term returns remain weak, and analysts see a modest gap between price and fair value estimates. So where does a reasonable valuation range actually land now?
Most Popular Narrative: 12% Undervalued
On the most followed valuation view, STAAR Surgical screens at a fair value of $28 against a last close of $24.56. This points to a modest discount that depends on execution rather than a bold recovery story.
The main thing that has to go right is that STAAR Surgical converts its strong position in China and rising ex-China EVO and EVO+ adoption into durable market share gains, while keeping operating expenses near the targeted 2026 level and executing on the Nidau, Switzerland ramp to support margins and supply.
See why 8 investors see STAAR Surgical as 12% undervalued.
Result: Fair Value of $28 (UNDERVALUED)
Still, the whole STAAR Surgical story leans heavily on China mix improving and the Nidau shift easing tariff pressure. Setbacks on either front could quickly erode that 12% undervaluation narrative.
Find out about the key risks to this STAAR Surgical narrative.
Another View: What STAAR Surgical’s Sales Multiple Is Telling You
There is a twist when the fair value story meets the sales multiple. STAAR Surgical trades on a P/S of 3.6x, while both its peer group and its fair ratio sit closer to 3x. That richer tag implies less room for error. If growth or margins disappoint, where does that leave the share price?
To see how this price-to-sales gap stacks up against peers and the fair ratio, and what that might mean for valuation risk in practice, See what the numbers say about this price — find out in our valuation breakdown.
For a visual read on how the market currently prices STAAR Surgical against the wider sector on this metric,
Next Steps
Short term optimism around STAAR Surgical only matters if you can see the risks and rewards side by side and decide where you stand. Move quickly, review both angles, and weigh up the balance of 3 key rewards and 1 important warning sign
Looking for more STAAR Surgical investment ideas?
Do not stop your research at a single stock. A broader watchlist gives you options when the story changes and helps you spot better risk reward trade offs.
- Target potential mispricings by scanning a curated pool of companies that score well on quality and valuation screens through the 29 high quality undervalued stocks.
- Protect your downside by focusing on resilient businesses screened for robust finances using the 30 resilient stocks with low risk scores.
- Get ahead of the crowd by reviewing a focused set of lesser known opportunities surfaced in the 18 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com